The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.

A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...

Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging ...

Physiologic pacing of the His-Purkinje conduction system is feasible in patients who require a permanent pacemaker following TAVR and this alternative pacing method did not interfere with ejection ...

Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Cardiac resynchronization therapy is a key treatment for patients with HFrEF and electrical dyssynchrony, such as LBBB. While ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) ...

Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for ...

NEW ORLEANS -- Among patients with heart failure, conduction system pacing-guided cardiac resynchronization therapy was associated with improvements in left ventricular ejection fraction (LVEF) ...

The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate ...

Please provide your email address to receive an email when new articles are posted on . Left bundle branch pacing was achieved for the first time via leadless pacemaker. Implantation failure rate was ...

Pacing as a device therapy for heart failure (HF) is headed for what is probably its next big advance. After decades of biventricular (BiV) pacemaker success in resynchronizing the ventricles and ...